BBP - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Products ETF (BBP)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has shown strong gains so far this year, indicating positive momentum in its biotech holdings.
Healthy Performance Among Top Holdings
Most of the top 10 stocks, including names like Crinetics and Iovance, have delivered strong year-to-date returns that support the fund’s overall results.
Moderate Expense Ratio
The fund’s expense ratio is reasonably low for a specialized biotech product, helping investors keep more of their returns.
Negative Factors
Heavy Sector Concentration
Nearly all assets are in the health care sector, so the ETF is highly sensitive to swings in biotech and pharmaceutical markets.
Single-Country Exposure
The fund is almost entirely invested in U.S. companies, offering little geographic diversification if the U.S. market faces biotech-specific challenges.
Some Lagging Top Holdings
A few of the larger positions, such as Verastem and Nuvation Bio, have shown weak year-to-date performance, which can drag on the ETF’s returns if the weakness continues.
BBP vs. SPDR S&P 500 ETF (SPY)
AUM119.89M
RegionNorth America
Expense Ratio0.34%
Beta0.89
IssuerVirtus
Inception DateDec 17, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedLifeSci Biotechnology Products Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,957
30 Day Avg. Volume8,789
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
152.40Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering67
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBP Summary
The Virtus LifeSci Biotech Products ETF (BBP) is a fund that follows the LifeSci Biotechnology Products Index, focusing on U.S. biotech companies in the health care sector. It holds firms that develop and sell new drugs and medical treatments, including names like Agios Pharma and BridgeBio Pharma. Someone might invest in BBP to seek long-term growth from cutting-edge medical breakthroughs and to get diversified exposure to many biotech stocks in a single investment. However, this ETF is heavily tied to the biotech industry, which can be very volatile and may rise or fall sharply with news about drug approvals or failures.
How much will it cost me?The Virtus LifeSci Biotech Products ETF (BBP) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like biotechnology that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Products ETF (BBP) could benefit from advancements in biotechnology and increased demand for innovative medical treatments, particularly in the U.S., where it is focused. However, it may face challenges from regulatory hurdles, high research and development costs, or broader economic downturns that could impact funding and growth in the biotech sector.
BBP Top 10 Holdings
BBP is a pure-play U.S. biotech fund, and its story right now is all about a handful of drug developers setting the tone. Iovance Biotherapeutics and Protagonist Therapeutics have been rising, giving the ETF a lift as investors bet on their pipelines and recent momentum. Crinetics and BridgeBio are also pulling their weight, adding steady strength. On the flip side, Nuvation Bio and Verastem have been lagging, acting like small anchors on performance. With nearly all exposure in health care and biotech, BBP is a focused bet on cutting-edge therapies rather than broad market stability.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 3.77% | $4.52M | $55.45B | 542.26% | 59 Neutral | |
| Crinetics Pharmaceuticals | 2.92% | $3.50M | $8.99B | 174.36% | 61 Neutral | |
| Omeros | 2.62% | $3.14M | $1.40B | 340.18% | 40 Underperform | |
| Iovance Biotherapeutics | 2.45% | $2.94M | $3.65B | 244.49% | 50 Neutral | |
| Verastem | 2.05% | $2.46M | $621.27M | -20.45% | 44 Neutral | |
| Precigen | 1.94% | $2.33M | $2.57B | 70.89% | 48 Neutral | |
| Halozyme | 1.86% | $2.24M | $12.33B | 49.90% | 73 Outperform | |
| Kiniksa Pharmaceuticals | 1.83% | $2.20M | $6.19B | 138.90% | 72 Outperform | |
| Zai Lab | 1.82% | $2.18M | $2.87B | -23.66% | 48 Neutral | |
| Kura Oncology | 1.78% | $2.14M | $1.10B | 79.29% | 47 Neutral |
BBP Technical Analysis
Positive
―
Price Trends
98.69
Positive
92.36
Positive
86.59
Positive
Market Momentum
3.14
Negative
68.75
Neutral
82.33
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 101.91, equal to the 50-day MA of 98.69, and equal to the 200-day MA of 86.59, indicating a bullish trend. The MACD of 3.14 indicates Negative momentum. The RSI at 68.75 is Neutral, neither overbought nor oversold. The STOCH value of 82.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBP.
BBP Peer Comparison
Comparison Results
Performance Comparison
BBP
Virtus LifeSci Biotech Products ETF
108.66
40.95
60.48%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PBE
Invesco Dynamic Biotechnology & Genome ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents